Positioning development programs for commercial success
Maximizing the value of a portfolio or an asset requires key elements to be in perfect alignment: alignment among scientific and commercial variables to ensure that development programs are addressing the right populations and markets; alignment with the payer and health system expectations that dictate whether the value of innovations will be recognized; and alignment across the cross-functional teams whose collective expertise is required to execute on development and commercialization plans.
Shift Health helps leaders—from multinational companies and smaller enterprises alike—achieve the alignment for successful product development. We efficiently collect the intelligence to understand a disease area and identify priority patient segments; we engage directly with payers, providers and patients to value-test hypothetical product profiles and expose nuances that differentiate development programs; and we work with internal teams to co-create market access strategies that position companies to mitigate risk and reach the market as quickly as possible.
R&D Strategy – Commercialization Plan – Market Access
A top-5 pharmaceutical company sought the perspectives of payers in the US and major EU markets to ensure that the value of an innovative vaccine would ultimately be recognized by health systems.
A multinational pharmaceutical company sought support in developing a strategy to partner with public/academic cancer patient data repositories to advance its own R&D programs.
To support a mid-stage clinical development program, a top-5 pharmaceutical company engaged Shift Health to obtain an understanding of physicians’ decision-making process with alternative therapies.
A player in the medical cannabis space required support to uncover and catalogue scientific evidence that established the link between specific cannabis-based metabolites and their therapeutic benefit.
Recognizing the dynamic nature of the psychiatry therapeutic arena, a top-5 pharmaceutical company required support in characterizing and prioritizing the stakeholder environment to inform how Medical Affairs could work with other functions to optimize patient care.
A leading pharmaceutical company required support in identifying and planning for risks and scenarios that could arise during a multinational Phase 3 vaccine clinical trial.